On this page
Delhi court permanently bars Sainus Pharma from using Udaan mark in RSPL Health case
Our read
RSPL turns its Udan court victory into a wider anti-counterfeit and lookalike crackdown, strengthening legitimate shelf presence in value feminine hygiene.
For operators
RSPL Health’s permanent injunction reinforces the need for FMCG operators to monitor lookalike branding and act quickly to protect consumer trust in high-frequency categories.
Watch
New RSPL cease-and-desist actions, raids or court filings involving similar feminine-hygiene marks.
The report,
A Delhi court permanently barred Hyderabad-based Sainus Pharma from using the Udaan trademark, finding it deceptively similar to RSPL Health’s registered Udan sanitary-napkin mark. Seized counterfeit products and infringing packaging must be handed to RSPL for destruction.
Reported figures
From the report. Source details below
- 2007
- Aug. 13
Why it matters for the brand
For acquirers and partners, the case highlights the value of trademark diligence and enforceable brand rights when evaluating consumer-health assets.
What to track next
- Marketplace delistings and distributor recalls of Sainus Pharma products.
- A Sainus Pharma appeal, rebranding announcement or launch of replacement packaging.
- RSPL marketing, trade promotions or distribution expansion for Udan in southern and value-focused markets.
- Evidence of counterfeit Udan products resurfacing under altered labels or through online sellers.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- RSPL is likely to issue distributor and marketplace notices requiring removal of Udaan-branded inventory and listings.
- RSPL may intensify trademark surveillance across feminine-hygiene packaging, pharmacy wholesalers and regional e-commerce sellers.
- Sainus Pharma may rebrand, seek to clear remaining inventory without the disputed mark, or challenge implementation details while complying with the injunction.
- Competitors may review naming and packaging for phonetic similarity risk, especially around low-cost sanitary-napkin brands.
The counter-case
The case against this reading — not reported by the source.
The injunction is a narrow legal win, not necessarily evidence of stronger consumer demand, pricing power, or category growth for RSPL Health. Enforcement costs, fragmented counterfeit supply chains, and copycat marks may persist despite the order.